<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BCG (BACILLUS CALMETTE-GUÉRIN) VACCINE</span><br/>(ba-cil'lus cal'met-te guer'in)<br/><span class="topboxtradename">Tice, </span><span class="topboxtradename">TheraCys<br/></span><b>Classifications:</b> <span class="classification">vaccine</span>; <span class="classification">antineoplastic</span>; <span class="classification">immunomodulator</span>; <span class="classification">biological response modifier</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 81 mg, 120 mg powder for suspension</p>
<h1><a name="action">Actions</a></h1>
<p>BCG vaccine is an immunization agent for tuberculosis (TB). It is an attenuated strain of the bacillus Calmette and Guérin
         strain of <i>Mycobacterium bovis</i>. BCG vaccine stimulates the reticuloendothelial system (RES) to produce macrophages that do not allow mycobacteria to multiply.
         BCG live is used intravesically as a biological response modifier for bladder cancer in situ. BCG live is thought to cause
         a local, chronic inflammatory response involving macrophage and leukocyte infiltration of the bladder. This local inflammatory
         response leads to destruction of superficial tumor cells.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>BCG is active immunotherapy, which stimulates the immune mechanism to reject the tumor. It enhances the cytotoxicity of macrophages.</p>
<h1><a name="uses">Uses</a></h1>
<p>To protect tuberculin skin test-negative infants and children, and groups with an excessive rate of new TB infections; carcinoma
         in situ of the bladder.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Malignant melanoma.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Impaired immune responses, immunosuppressive corticosteroid therapy, asymptomatic carriers with positive HIV serology; fever;
         UTI; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity to BCG; pregnancy (category C).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prevention of Tuberculosis (Tice only)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Intradermal</span> 0.1 mL<br/><span class="rdage">Adult/Child:</span> <span class="rdroute">Percutaneous</span> &gt;<i>1 mo</i>, After reconstitution, 0.20.3 mL of vaccine is dropped onto the cleansed surface of the skin and administered using
               a multiple-puncture disk applied through the vaccine<br/><span class="rdage">Child:</span> <span class="rdroute">Intradermal</span> 3 mo, 0.05 mL; &gt;<i>3 mo</i>, 0.1 mL<br/><span class="rdage">Child:</span> <span class="rdroute">Percutaneous</span> 1 mo, reduce adult dose by ½ (reconstitute with 2 mL), may need to revaccinate with full dose at 1 y; same as adult<br/><br/><span class="indicationtitle">Carcinoma of the Bladder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Intravesical</span> 3 vials of <b>TheraCys</b> at 27 mg each (81 mg total) of BCG reconstituted with accompanying diluent 714 d after biopsies/transurethral resections
               once/wk for 6 wk plus one treatment at 3, 6, 12, 18, and 24 mo; 1 vial of <b>Tice</b> per intravesical instillation once/wk for 6 wk plus one treatment/mo for 612 mo<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p><b><small>WARNING: </small></b>Do not inject intravenously, subcutaneously, or intradermally.
      </p><span class="adminroutetype">Percutaneous</span><br/><ul>
<li>Prepare solution: Add 1 mL sterile water for injection to 1 ampul of vaccine. Draw into syringe and expel back into ampul
            3 times to mix.
         </li>
<li>Administer drug by dropping 0.20.3 mL onto clean surface of skin; then use a sterile multiple-puncture disk to create
            percutaneous skin punctures.
         </li>
<li>Instruct to keep vaccination site dry for 24 h; no dressing is needed.</li>
<li>Important: Avoid contact with BCG vaccine during preparation and administration.</li>
<li>Store dry BCG powder, reconstituted vaccine, and diluent refrigerated at 2°8° C (35°46° F).
            Use reconstituted solution within 2 h.
         </li>
</ul><span class="adminroutetype">Intravesical Instillation</span><br/><ul>
<li>
<b>TheraCys:</b> Dilute 3 vials of <b>TheraCys</b> in 50 mL of sterile preservative free NS and instill into bladder slowly by gravity flow via urethral catheter. Patient retains
            suspension for 2 h and then voids.
         </li>
<li>
<b>Tice:</b> Instill 1 vial of <b>Tice</b> intravesically once/wk for 6 wk plus one per mo for 612 mo.
         </li>
<li>Important: Exercise care, when handling BCG vaccine to avoid contact with the product.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Intravesical administration: <span class="speceff-common">malaise</span>, dizziness, headache, weakness. <span class="typehead"> Endocrine:</span> Hyperpyrexia. <span class="typehead">GI:</span> Abdominal pain, anorexia, constipation, nausea, vomiting, diarrhea; hepatic dysfunction following intratumor injection, granulomatous
      hepatitis. <span class="typehead">Urogenital:</span> Intravesical administration: bladder spasms, clot retention, decreased bladder capacity, decreased urine flow, <span class="speceff-common">dysuria, hematuria,</span> incontinence, nocturia, UTI, cystitis, hemorrhagic cystitis, penile pain, prostatism. <span class="typehead">Hematologic:</span> Thrombocytopenia, eosinophilia, <span class="speceff-common">anemia,</span> leukopenia, <span class="speceff-life">disseminated intravascular coagulation</span>. <span class="typehead">Respiratory:</span> Cough (rare), pulmonary granulomas, pulmonary infection. <span class="typehead">Skin:</span> Abscess with recurrent discharge, red papule that scales or ulcerates in about 56 wk, dermatomyositis, granulomas at
      injection site 46 wk after inoculation, keloid formation, lupus vulgaris. <span class="typehead"> Body as a Whole:</span>  Systemic BCG infection, <span class="speceff-common">chills, flu-like syndrome,</span>
<span class="speceff-life">anaphylaxis</span> (rare), allergic reactions, lymphadenitis. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Prior BCG vaccination may result in false-positive <span class="alt">tuberculin skin test (PPD).</span> Following BCG vaccination, tuberculin sensitivity may persist for months to years.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Concurrent antimycobacterial therapy (<b>aminosalicylic acid,</b>
<b>capreomycin,</b>
<b>cycloserine,</b>
<b>ethambutol,</b>
<b>ethionamide,</b>
<b>isoniazid,</b>
<b>pyrazinamide,</b>
<b>rifabutin,</b>
<b>rifampin,</b>
<b>streptomycin</b>) that inhibits multiplication of BCG bacilli has the potential to antagonize or altogether negate the BCG vaccine-mediated
      immune response. <b>Cyclosporine</b> may reduce the immunologic response to BCG vaccine. <b>
<i>Cytomegalovirus immune globulin</i>
</b> and other live vaccines (measles/mumps/rubella, oral polio) may interfere with immune response to BCG. Previous vaccination
      with or other exposure to BCG may induce variable sensitivity to tuberculin. A greater booster effect following repeat tuberculin
      testing has been reported in individuals with prior BCG vaccination when compared with individuals without prior vaccination. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1> Not studied. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of systemic BCG infection: Fever, chills, severe malaise, or cough.</li>
<li>Culture blood and urine, if systemic infection is suspected.</li>
<li>Assess for regional lymph node enlargement and report fistula formation.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Review potential adverse effects.</li>
<li>Keep vaccination site clean until local reaction has subsided.</li>
<li>Do not breast feed until cleared to do so by physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>